Key Takeaways FOLD stands out after agreeing to a $14.50-per-share buyout by BioMarin, expected to be closed in Q2 2026.FOLD's Galafold drove over 80% of sales in 9M 2025, while Pombiliti plus Opfolda showed strong initial growth.RIGL's revenues are powered by Tavalisse, with added momentum from Rezlidhia and newly acquired Gavreto.Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) appeal to growth-focused investors as they target rare diseases, where small patient populations can still support str ...